Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for prevention of delirium in advanced cancer inpatients
ACTRN12616001618448Phase 3Completed
- Sponsor
- University of Technology Sydney
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delirium comparing Melatonin with Placebo (2 arms). Primary endpoint: Number of delirium-free days. Started Jul 2017; status: completed.
02
Drugs
melatonin
03
Conditions
delirium
Beyond the preview
Go deeper on ACTRN12616001618448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001618448.